LOGNER CAP
November 30, 2017
POLKA-OZ TAB
November 30, 2017

NIZBRO CAP

(ACEBROPHYLLINE 100 MG CAP)

SKU: ec3913441a53 Categories: ,
Description

Packing: – 10X10
M.R.P: – 790
ACEBROPHYLLINE HAS 3 ACTIONS NAMELY BRONCHODILATION, MUCOREGULATION & ANTI-INFLAMMATORY ACTION.
PHARMACOLOGY
A.)PHARMACODYNAMICS: Acebrophylline inhibits intracellular phosphodiesterase associated significantly reduce the airway inflammation and obstruction in chronic stages. Acebrophylline increases the synthesis and release of alveolar surfactant, resulting in triple action: mucoregulation, stimulation of bronchoalveolar clearance, and anti-inflammatory-antireactive effect. In patients with chronic obstructive bronchitis, given the drug for 10-20 days, there was a good reduction in expectorate Viscosity.with cAMP levels and facilitates bronchial muscles relaxation. Acebrophylline selectively inhibits phosphatidylcholine and phospholipase A, TNF-alpha and leukotrienes. Inhibition of such pro-inflammatory mediators can.
B.)PHARMACOKINETICS:
• Absorption: – 200mg oral acebrophylline, the two components of the molecule ambroxol and theophylline-7-acetic acid are released in the stomach and absorbed in the intestine, reaching optimal concentrations of ambroxol within 2hrs and of theophylline-7-acetic acid after 1 hr.
• Half-Life: – The plasma half life varies from 4 to 9 hrs after oral administration.
• Metabolism: – The drug is metabolized in the liver and eliminated renally.
Indications: Treatment of adult patients with COPD and bronchial asthma.

Additional information
Pack Type

Pack Size

Download Product List
Contact Us
close slider